Phase 1/2 Clinical Trial for the Evaluation of Ingenol Mebutate for Actinic Cheilitis
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 20 Jun 2019
Price : $35 *
At a glance
- Drugs Ingenol mebutate (Primary)
- Indications Actinic keratosis
- Focus Therapeutic Use
- Acronyms EIMAC
- 17 Jun 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 25 Feb 2019 Planned End Date changed from 1 Apr 2020 to 1 Apr 2022.
- 25 Feb 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Sep 2021.